Advances in drug treatment of portal hypertension

World Chinese Journal of Digestology

Volumn 16, Issue 33, 2008, Pages 3775-3781

  Ma, Xiao ^a   Liu, Bing Rong ^a  

^a Medical University   (China)

Author keywords

Drug; Portal hypertension; Treatment

Indexed keywords

HEPATIC ENCEPHALOPATHY; HUMAN; LIVER BLOOD FLOW; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASCULAR RESISTANCE;

EID: 60049087256     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v16.i33.3775     Document Type: Review

References (67)

1. Reynaert H, Urbain D, Geerts A. Regulation of sinusoidal perfusion in portal hypertension. Anat Rec (Hoboken) 2008; 291: 693-698
2. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-581
3. Chinese source
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415
5. Møller S, Gülberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995; 23: 135-144
6. Moore K, Wendon j, Frazer M, Kararu j, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 1774-1778
7. Shao R, Rockey DC. Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing. J Cell Physiol 2002; 191: 342-350
8. Yokomori H, Oda M, Ogi M, Yoshimura K, Nomura M, Fujimaki K, Kamegaya Y, Tsukada N, Ishii H. Endothelin-1 suppresses plasma membrane Ca++- ATPase, concomitant with contraction of hepatic sinusoidal endothelial fenestrae. Am J Pathol 2003; 162: 557-566
9. La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 1995; 22: 315-323
10. Cahill PA, Hou MC, Hendrickson R, Wang YN, Zhang S, Redmond EM, Sitzman JV. Increased expression of endothelin receptors in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics. Hepatology 1998; 28: 396-403
11. Kojima H, Sakurai S, Kuriyama S, Yoshiji H, Imazu H, Uemura M, Nakatani Y, Yamao J, Fukui H. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001; 34: 805-811
12. Yokomori H, Oda M, Yasogawa Y, Nishi Y, Ogi M, Takahashi M, Ishii H. Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver. Am J Pathol 2001; 159: 1353-1362
13. Chinese source
14. De Gottardi A, Shaw S, Sägesser H, Reichen j. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats. J Hepatol 2000; 33: 733-737
15. Chinese source
16. Watanabe N, Takashimizu S, Nishizaki Y, Kojima S, Kagawa T, Matsuzaki S. An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation. J Gastroenterol 2007; 42: 775-782
17. Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Hou MC, Huang HC, Lee SD. Effects of endothelin-1 on portal-systemic collaterals of common bile duct- ligated cirrhotic rats. Eur J Clin Invest 2004; 34: 290-296
18. Chinese source
19. Thirunavukkarasu C, Yang Y, Subbotin VM, Harvey SA, Fung j, Gandhi CR. Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats. Gut 2004; 53: 1010-1019
20. Tripathi D, Therapondos G, Ferguson JW, Newby DE, Webb DJ Hayes PC. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006; 55: 1290-1295
21. Borroni G, Salerno F, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A, Visentin S, Panzeri A, de Franchis R. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002; 37: 315-321
22. Kamath PS. Esophageal variceal bleeding: primary prophylaxis. Clin Gastroenterol Hepatol 2005; 3: 90-93
23. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, Tallet D, del Soldato P, Morelli A. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001; 98: 8897-8902
24. Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuta G, Clerici C, Baldoni M, Del Soldato P, Morelli A. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003; 39: 932-939
25. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003; 39: 940-946
26. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007; 132: 709-719
27. Chinese source
28. Van de Casteele M, Omasta A, Jans sens S, Roskams T, Desmet V, Nevens F, Fevery J. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002; 51: 440-445
29. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-748
30. Zhang ZQ, Qiu jF, Luo M, Sun YW, Zhao G, Chen W, Liu H, Wu ZY. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance. J Gastroenterol Hepatol 2008; 23: e487-e493
31. Hennenberg M, Biecker E, Trebicka J, jochem K, Zhou Q, Schmidt M, jakobs KH, Sauerbruch T, Heller j. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006; 130: 838-854
32. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N, Taketomi A, Hashizume M, Shimokawa H, Maehara Y. Defective endothelial nitric oxide synthase signaling is mediated by rho- kinase activation in rats with secondary biliary cirrhosis. Hepatology 2008; 47: 966-977
33. Trebicka j, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller j. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46: 242-253
34. Fernando B, Marley R, Holt S, Anand R, Harry D, Sanderson P, Smith R, Hamilton G, Moore K. N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 1998; 28: 689-694
35. Marley R, Holt S, Fernando B, Harry D, Anand R, Goodier D, Davies S, Moore K. Lipoic acid prevents development of the hyperdynamic circulation in anesthetized rats with biliary cirrhosis. Hepatology 1999;29: 1358-1363
36. Sakamoto M, Uen T, Nakamura T, Hashimoto O, Sakata R, Kin M, Ogata R, Kawaguch T, Torimura T, Sata M. Estrogen upregulates nitric oxide synthase expression in cultured rat hepatic sinusoidal endothelial cells. J Hepatol 2001; 34: 858-864
37. Sakamoto M, Ueno T, Nakamura T, Sakata R, Hasimoto O, Torimura T, Sata M. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen. Eur J Clin Invest 2005; 35: 220-225
38. Baik SK, Park DH, Kim MY, Choi Yj, Kim HS, Lee DK, Kwon SO, Kim Yj, Park JW, Chang Sj. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. J Gastroenterol 2003; 38: 1150-1154
39. Tsai YT, Lin HC, Lee FY, Hou MC, Wang SS, Lee SD. Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis. Proc Natl Sci Counc Repub China B 19%; 20: 44-50
40. Chinese source
41. Schneider AW, Kalk jF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-339
42. Chinese source
43. Helmy A, jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000; 118: 565-572
44. Tripathi D, Therapondos G, Lui HF, johnston N, Webb DJ, Hayes PC. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol 2004; 99: 390-394
45. Park DH, Baik SK, Choi YH, Kim MY, Rhim DW, Kim jW, Kwon SO, Cho MY, Kim CH, Ahn SC. [Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile duct-ligated rats] Korean J Hepatol 2007; 13: 61-69
46. Chinese source
47. Debernardi-Venon W, Barletti C, Alessandria C, Marzano A, Baronio M, Todros L, Saracco G, Repici A, Rizzetto M. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dtg Dis Sci 2002; 47: 401-404
48. Schepke M, Wiest R, Flacke S, Heller j, Stoffel- Wagner B, Herold T, Ghauri M, Sauerbruch T. Irbesartan plus low-dose propranolol versus low- dose propranolol alone in cirrhosis: a placebo- controlled, double-blind study. Am J Gastroenterol 2008; 103: 1152-1158
49. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology 2003; 125: 556-571
50. Tu CT, Guo jS, Wang M, Wang JY. Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. J Gastroenterol Hepatol 2007; 22: 877-884
51. Horrillo R, Planaguma A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Cla?̀ria j. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther 2007; 323: 778-786
52. Chinese source
53. Li T, Weng SG, Leng XS, Peng jR, Wei YH, Mou DC, Wang WX. Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells. Hepatobiliary Pancreat Dis Int 2006; 5: 96-100
54. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan- Lluka Lj, Ramm GA, Mann DA. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006; 169: 861-876
55. Talwalkar JA, Kamath PS. An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis. Am J Med 2004; 116: 759-766
56. Bosch j, Abraldes jG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38 Suppl 1: S54-S68
57. Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, Cavallarin G, Bolognesi M, Donada C, Bellini B, Torboli P, Gatta A. A placebo- controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127: 476-484
58. Groszmann Rj, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R. Beta- blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-2261
59. Garcia-Tsao G. Preventing the development of varices in cirrhosis. J Clin Gastroenterol 2007; 41 Supp1 3: S300-S304
60. Khuroo MS, Khuroo NS, Farahat KL, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21: 347-361
61. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, Masini E, Perfetto F, Tarquini R, Gentilini P, Laffi G. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19-27
62. Spahr L, Martin PY, Giostra E, Niederberger M, Lang U, Capponi A, Hadengue A. Acute effects of nitric oxide synthase inhibition on systemic, hepatic, and renal hemodynamics in patients with cirrhosis and ascites. J Investig Med 2002; 50: 116-124
63. Kalambokis G, Economou M, Fotopoulos A, Bokharhii jA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Dis Sci 2005; 50: 1771-1777
64. Vanheule E, Geerts AM, Reynaert H, Van Vlierberghe H, Geerts A, De Vos M, Colle I. Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy, liver Int 2008; 28: 107-116
65. Yang jF, Wu Xj, Li jS, Cao jM, Han jM. Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. Eur J Gastroenterol Hepatol 2005; 17: 53-57
66. Chinese source
67. Chinese source